Anonymous: "History of Changes for Study: NCT01421186 A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma Archive History for NCT01421186 https", , 18 March 2015 (2015-03-18), XP055539141, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history /NCT01421186?V_9=View#StudyPageTop [retrieved on 2019-01-08] (B1)

BLOOD, vol. 130, no. 8, 2017, pages 974-981, (B1)

CUESTA-MATEOS: FRONT IMMUNOL, vol. 8, 2018, page 1936, (B1)

CURR HEMATOL MALIG REP, vol. 4, 2017, pages 344-357, (B1)

HARTLEPP ET AL: "800 POSTER MOR202 - a fully human antibody targeting CD38 for the treatment of multiple myeloma and other forms of blood-borne malignancies", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 5, no. 4, 1 September 2007 (2007-09-01), page 117, XP022333014, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(07)70533-5 (B1)

KATHARINA TEILUF ET AL: "[alpha]-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma", ONCOTARGET, vol. 6, no. 7, 10 December 2014 (2014-12-10), pages 4692-4703, XP055286741, DOI: 10.18632/oncotarget.2986 (B1)

WO-A1-2012/041800 (B1)

Michael Karl Bauer: "CD38: A Unique Target In Multiple Myeloma", , 28 March 2014 (2014-03-28), XP055538985, Retrieved from the Internet: URL:https://ir.genmab.com/static-files/961 08e16-8308-4ace-afc5-d7ef2689ddc6 [retrieved on 2019-01-08] (B1)

N ENGL J MED, vol. 375, 2016, pages 1319-1331, (B1)

NIELS W.C.J. VAN DE DONK ET AL: "CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance", FRONTIERS IN IMMUNOLOGY, vol. 9, 20 September 2018 (2018-09-20), XP055611801, DOI: 10.3389/fimmu.2018.02134 (B1)

PROCEED. AM. SOC. CLIN. ONCOL. (ASCO) ANN. MEETING; 2-7 JUNE 2016, CHICAGO, IL; ABSTRACT 8012, 2016, (B1)

Stephen A Beers ET AL: "Blood Spotlight Influence of immunoglobulin isotype on therapeutic antibody function", , 13 January 2016 (2016-01-13), XP055617716, DOI: 10.1182/blood-2015-09- Retrieved from the Internet: URL:http://www.bloodjournal.org/content/bl oodjournal/127/9/1097.full.pdf [retrieved on 2019-09-03] (B1)

Marc S Raab ET AL: "A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)", , 2 June 2015 (2015-06-02), XP055286751, Retrieved from the Internet: URL:https://www.morphosys.com/sites/defaul t/files/phone-conferences/downloads/asco_m or202_poster_final_for_print_21.05.15.pdf [retrieved on 2016-07-07] (B1)